2017

  • New Options in Wireless Remote Patient Monitoring

    May 24, 2017

    New Options in Wireless Remote Patient Monitoring: Interview with Michael Mazzini, MD Author(s): Interview by Jodie Elrod Issue Number: Volume 17 - Issue 5 - May 2017 Dr. Michael Mazzini is with North Suburban Cardiology Associates in Stoneham, Massachusetts. In this interview, we speak with him about his use of the MoMe® Kardia wireless remote patient monitoring system (InfoBionic), a 3-in-1 device that acquires and stores ECG and motion data, and transmits it through the company’s cloud-based system for analysis.   Press Release

    Read More
  • Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke

    May 15, 2017

    Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke Phase 3-ready program complements Biogen’s ongoing development efforts in stroke Biogen will pay a $120 million upfront payment plus potential milestone and royalty payments May 15, 2017 07:30 AM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today that it has completed an asset purchase of Remedy Pharmaceuticals’ Phase 3 candidate, CIRARA™ (intravenous glyburide). The target indication for CIRARA is large hemispheric infarction (LHI), a sever

    Read More
  • Simple New Test Might Be a Better Way to Diagnose Gestational Diabetes

    April 28, 2017

    Link to publication below: Mellitus Study Mentioned in "What to Expect" Magazine

    Read More
  • Mellitus Reports Publication of Investigator-Initiated Study Supporting Glycated CD59 as a Novel Alternative for Gestational Diabetes Screening

    April 27, 2017

    Mellitus Reports Publication of Investigator-Initiated Study Supporting Glycated CD59 as a Novel Alternative for Gestational Diabetes Screening -A single blood test to measure GCD59 at week 24-28 of gestation identified women with gestational diabetes with high sensitivity and specificity- -GCD59 technology to advance diabetes detection and monitoring under exclusive license by Mellitus from Harvard University- BOSTON, Mass., April 27, 2017 – Mellitus, LLC today reported the publication of results from a prospective, investigator-initiated study conducted at Brigham and Women’s Hospi

    Read More
  • InfoBionic Names Industry Veteran Stuart Long Chief Executive Officer

    April 4, 2017

    InfoBionic Names Industry Veteran Stuart Long Chief Executive Officer Signals next phase of expansion with cardiologists and electrophysiologists to improve the quality of patient care, reduce costs, and maximize reimbursement. Press Release

    Read More
  • Herantis Pharma’s clinical study with Lymfactin advances to high dose level

    March 6, 2017

    Herantis Pharma’s clinical study with Lymfactin advances to high dose level Herantis Pharma PlcCompany release 6 March 2017 at 10:00 am Herantis Pharma Plc’s (“Herantis”) clinical study with the company’s innovative gene therapy investigational product Lymfactin® for the treatment of secondary lymphedema has advanced to highest planned dose level owing to good reported safety. A Data Monitoring Committee of independent experts recommended proceeding to high dose treatments after assessing safety data on the previously treated patients. Following the recommendation, the first high

    Read More
  • miRagen Therapeutics Completes merger with Signal Genetics and Concurrent $40.7M Equity Financing

    February 13, 2017

    BOULDER, CO – February 13, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced the completion of its merger with Signal Genetics, Inc., effective February 13, 2017.  Concurrent with the closing of the merger, miRagen received gross proceeds of $40.7 million in new equity investment from a combination of current and new miRagen investors, including Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd.,

    Read More
  • Nido Surgical Raises $1.3M Series A Led By Broadview Ventures

    February 7, 2017

    Nido Surgical Raises $1.3M Series A Led By Broadview Ventures BOSTON, Feb. 7, 2017 --Nido Surgical, Inc., a development-stage medical device company focused on creating innovative solutions for beating heart surgery, has raised $1.3 million in a Series A financing led by Broadview Ventures (Boston, MA). The funds will be used to finance the development and First-In-Man studies of Nido Surgical' platform product, the CardioPort™. Nido Surgical has also received a $1.4 million Small Business Technology Transfer (STTR) grant from the National Institutes of Health to support this work.

    Read More
  • Remedy Granted Orphan Drug Designation

    January 16, 2017

    Remedy Pharmaceuticals’ CIRARA Granted Orphan Drug Designation For Treatment of Severe Cerebral Edema Caused By Acute Ischemic Stroke NEW YORK, New York, January 17, 2017 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatments to people affected by central nervous system related edema, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational drug, CIRARA, for treatment of severe cerebral edema in patients with acute ischemic stroke. Link to Press Release

    Read More